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Purpose: To assess the effectiveness and safety of Chi-
nese herbal medicine (CHM) for the treatment of acute pelvic
inﬂammatory disease (PID).
Methods: We undertook a systematic search for ran-
domised clinical trials of CHM for acute PID through seven
electronic databases from their inception to January 2014.
Two authors independently extracted data and assessed
the methodological quality of the included trials using the
Cochrane risk of bias tool. Revman 5.2 software was used for
data analysis with effect estimate presented as risk ratio and
mean difference with a 95% conﬁdence interval.
Results: Thirty-one trials involving 2860 participants with
acute PID were identiﬁed. All trials were methodologically
weak and at high risk of bias Twenty-one different herbal
medicineswere tested in the 31 trials. Pooling of data viameta-
analysis was impossible due to the clinical heterogeneity in
terms of participants, intervention and control. Fifteen out of
31 trials showed CHM used alone or combined with antibi-
otics was signiﬁcantly better than antibiotics on the number
of cured participants with PID. Three of four trials demon-
strated CHM used alone or combined with antibiotics reduced
the time to disappearance of lower abdominal pain and pelvic
mass compared to antibiotics. Data from two trials showed
CHM plus antibiotics was superior to antibiotics on incidence
of chronic pelvic pain after follow up of 3 months and PID
relapse after follow up of 1 year. Three of four trials showed
CHM plus antibiotics had shorter length of hospital stay than
antibiotics. No severe adverse events were reported and only
four trials reported mild adverse events.
Conclusion: CHM may be potentially effective in the treat-
ment of acute PID. However, due to poor methodological
quality of the included trials, current evidence is insufﬁcient
to support clinical use. Further rigorous trials are warranted.
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Purpose: Randomised controlled trials (RCTs) evaluate
effectiveness of Chinese herbal medicines (CHMs) in the West,
yet little is known regarding CHM adherence amongst these
populations. We aimed to evaluate feasibility of collecting
adherence data within a UK study and identify strategies for
improving adherence.
Methods: We conducted a feasibility study exploring CHM
for polycystic ovary syndrome, randomising 40 women to
either standardised CHMor individualised CHM. Thiswas pre-
scribed for 24 weeks at 8 g granules/dose, two dosages daily,
taken as a tea. Practitioners and participants were blinded.
We evaluated adherence usingMoriskyMedicationAdherence
Scale (MMAS) at Week 4 and end of study (EoS); weighing pre-
scriptions at Week 12 and EoS, and process data.
Results: Mean completion rates were high for MMAS
(87.5%). Weighing data was complete for 15 (37.5%) partic-
ipants, incomplete for 15 (37.5%) and absent for 10 (25%).
MMAS data suggests low adherence to both CHM interven-
tions at Week 4 and EoS. Small improvements within-group
were observed for both standardised CHM (MD 0.9, 95% CI -
0.3 to 2.0) and individualised CHM (MD 1.0, 95% CI 0. 3 to 1.8)
but which were statistically signiﬁcant only for individuali-
sed. When explored as a categorical variable, improvement
from low to medium or high adherence was found in 4 partic-
ipants from each of the two groups. We used weighing data to
estimate a mean of 65% (SD21.2) of CHMs were administered,
suggesting a dose of 10-11 g/day is more feasible. Process data
suggests adherence could be improved by changing adminis-
tration to tablet/capsules and reducing to once daily dosing.
Conclusion:Toour knowledge, this is the ﬁrst rigorous eval-
uation of CHM treatment adherence carried out in theUK. This
studyhasuncovered important ﬁndings regardingCHMadher-
ence in a Western population and will help inform the design
of the CHM intervention for a main study.
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